

Form PTO-1595 (Rev. 09/04)  
OMB No. 0651-0027 (exp. 6/30/2005)

U.S. DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office

## RECORDATION FORM COVER SHEET PATENTS ONLY

To the Director of the U.S. Patent and Trademark Office: Please record the attached documents or the new address(es) below.

### 1. Name of conveying party(ies)/Execution Date(s):

NeuronZ Ltd.

Execution Date(s) 10/12/04 and 10/15/04

Additional name(s) of conveying party(ies) attached? ☐ Yes ☒ No

### 3. Nature of conveyance:

- ☒ Assignment ☐ Merger  
☐ Security Agreement ☐ Change of Name  
☐ Government Interest Assignment  
☐ Executive Order 9424, Confirmatory License  
☐ Other \_\_\_\_\_

### 2. Name and address of receiving party(ies)

Name: Neuren Pharmaceuticals Ltd.

Internal Address: Level 3, 2-6 Park Avenue

Street Address: Level 3, 2-6 Park Avenue

City: Grafton, Auckland

State: \_\_\_\_\_

Country: New Zealand Zip: \_\_\_\_\_

Additional name(s) & address(es) attached? ☐ Yes ☒ No

### 4. Application or patent number(s):

A. Patent Application No.(s)

☐ This document is being filed together with a new application.

B. Patent No.(s)

6,812,208

Additional numbers attached? ☐ Yes ☒ No

### 5. Name and address to whom correspondence concerning document should be mailed:

Name: D. Benjamin Borson

Internal Address: Fliesler Meyer LLP

Street Address: \_\_\_\_\_

Four Embarcadero Center, 4th Floor

City: San Francisco

State: CA Zip: 94111-4156

Phone Number: 415.362.3800

Fax Number: 415.362.2928

Email Address: dbb@fdml.com

### 6. Total number of applications and patents involved:

1

### 7. Total fee (37 CFR 1.21(h) & 3.41) \$ 40.00

- ☐ Authorized to be charged by credit card  
☒ Authorized to be charged to deposit account  
☐ Enclosed  
☐ None required (government interest not affecting title)

### 8. Payment Information

a. Credit Card Last 4 Numbers \_\_\_\_\_  
 Expiration Date \_\_\_\_\_

b. Deposit Account Number 06-1325

Authorized User Name Fliesler Meyer LLP

### 9. Signature:

D. Benjamin Borson  
 Signature

December 27, 2004

Date

D. Benjamin Borson  
 Name of Person Signing

Reg. No.: 42,349

Total number of pages including cover sheet, attachments, and documents:

17

Documents to be recorded (including cover sheet) should be faxed to (703) 306-5995, or mailed to:  
 Mail Stop Assignment Recordation Services, Director of the USPTO, P.O. Box 1450, Alexandria, V.A. 22313-1450

**CORPORATE TO CORPORATE  
ASSIGNMENT OF PATENTS, APPLICATIONS, AND INVENTIONS**

WHEREAS, NeuronZ Ltd. (hereinafter termed "the Assignor"), a New Zealand company having a place of business at Level 3, 2-6 Park Avenue, Grafton, Auckland, New Zealand, is the owner of all right title and interest in the following patents and patent applications:

Title:	New peptide antagonists at glutamate and NMDA receptors
Inventors:	J.P. Bourguignon
Application No.:	PCT/SE94/00454
Attorney Docket No.:	NRNZ-1001WO

Title:	New peptide antagonists at glutamate and NMDA receptors
Inventors:	J.P. Bourguignon
Application No.:	10/087,011
Attorney Docket No.:	NRNZ-1001US2

Title:	New peptide antagonists at glutamate and NMDA receptors
Inventors:	J.P. Bourguignon
Patent No.:	US 5,804,550
Attorney Docket No.:	NRNZ-1001US0

Title:	New peptide antagonists at glutamate and NMDA receptors
Inventors:	J.P. Bourguignon
Patent No.:	AU 685,123
Attorney Docket No.:	NRNZ-1001AU0

Title:	New peptide antagonists at glutamate and NMDA receptors
Inventors:	J.P. Bourguignon
Application No.:	CA 2,162,924
Attorney Docket No.:	NRNZ-1001CA0

Title:	New peptide antagonists at glutamate and NMDA receptors
Inventors:	J.P. Bourguignon
Patent No.:	EP 697886
Attorney Docket No.:	NRNZ-1001EP0

Title:	New peptide antagonists at glutamate and NMDA receptors
Inventors:	J.P. Bourguignon
Application No.:	JP524705/1994
Attorney Docket No.:	NRNZ-1001JP0

Title:	Compositions and methods to improve neural outcome
Inventors:	Gluckman, Williams
Application No.:	1) NZ 250572 2) NZ 260091 3) NZ 264070
Attorney Docket No.:	NRNZ-1002L1,2,3

Title:	Compositions and methods to improve neural outcome
Inventors:	Gluckman, Williams
Application No.:	PCT/NZ94/00143
Attorney Docket No.:	NRNZ-1002WO

Title:	Use of tripeptide GPE for treating or preventing symptoms of Parkinson's disease
Inventors:	Gluckman, Williams, Guan, Krishnamurthi
Application No.	PCT/US02/16609
Attorney Docket No.:	NRNZ-1002WO3

Title:	Compositions and methods to improve neural outcome
Inventors:	Gluckman, Williams
Patent No.:	AU 700,838
Attorney Docket No.:	NRNZ-1002AU

Title:	Compositions and methods to improve neural outcome
Inventors:	Gluckman, Williams
Application No.:	NZ 330,758
Attorney Docket No.:	NRNZ-1002NZ

Title:	Compositions and methods to improve neural outcome
Inventors:	Gluckman, Williams
Application No.:	CA 2178711
Attorney Docket No.:	NRNZ-1002CA

Title:	Compositions and methods to improve neural outcome
Inventors:	Gluckman, Williams
Application No.:	CN 94195037.9
Attorney Docket No.:	NRNZ-1002CN

Title:	Compositions and methods to improve neural outcome
Inventors:	Gluckman, Williams
Application No.:	EP 95904702.8
Attorney Docket No.:	NRNZ-1002EP

Title:	Compositions and methods to improve neural outcome
Inventors:	Gluckman, Williams
Application No.:	JP 517338/95
Attorney Docket No.:	NRNZ-1002JP

Title:	Compositions and methods to improve neural outcome
Inventors:	Gluckman, Williams
Application No.:	US 08/656,331
Attorney Docket No.:	NRNZ-1002US0

Title:	Compositions and methods to improve neural outcome
Inventors:	Gluckman, Williams
Application No.:	US 08/907,918
Attorney Docket No.:	NRNZ-1002US1

Title:	Methods to improve neural outcome
Inventors:	Gluckman, Williams, Guan
Patent No.:	US 6,187,906
Attorney Docket No.:	NRNZ-1002US2

Title:	Methods to improve neural outcome
Inventors:	Gluckman, Williams, Guan, Krishnamurthi
Application No.:	US 09/866,536
Attorney Docket No.:	NRNZ-1002US3

Title:	Use of GPE to protect glial cells or non-dopaminergic cells from death from neural injury or disease
Inventors:	Gluckman, Williams
Patent No.:	US 6,780,848
Attorney Docket No.:	NRNZ-1002US4

Title:	Composition and methods to improve neural outcome
Inventors:	Gluckman, Krissansen, Kanwar, Sirimanne
Application No.:	US 10/119,386
Attorney Docket No.:	NRNZ-1002US5

Title:	Regulation of Neural Enzymes
Inventors:	Gluckman, Williams, Guan
Application No.:	NZ 299511 NZ 299512 NZ299513
Attorney Docket No.:	NRNZ-1003L

Title:	Regulation of Neural Enzymes
Inventors:	Gluckman, Williams, Guan
Application No.:	PCT/NZ97/00132
Attorney Docket No.:	NRNZ-1003WO

Title:	Regulation of Neural Enzymes
Inventors:	Gluckman, Williams, Guan
Patent No:	US 6,365,573
Attorney Docket No.:	NRNZ-1003US0

Title:	Regulation of Neural Enzymes
Inventors:	Gluckman, Williams, Guan
Application No. or Patent No.:	AU 743,412 NZ 335,544 CA 2,267,523 EP 97945108.5 JP 516411/98
Attorney Docket No.:	NRNZ-1003

Title:	Neuronal Rescue Agent
Inventors:	Gluckman, Williams, Wu, Hughes, Lai
Application No.:	US 10/157,542
Attorney Docket No.:	NRNZ-1004US1

Title:	Neuronal Rescue Agent
Inventors:	Gluckman, Williams, Wu, Hughes, Lai
Application No.:	US 09/508,897
Attorney Docket No.:	NRNZ-1004US0

Title:	Receptor
Inventors:	Gluckman, Clark, Sheepens, Tong, Gilmour
Application No.:	NZ 527,027
Attorney Docket No.:	NRNZ-1007

Title:	GPE analogues
Inventors:	Gluckman, Alexi
Application No.:	PCT/US01/41883 US 10/362,266 EP 01968959.5
Attorney Docket No.:	NRNZ-1008

Title:	Functional proteomics using double phage display screening
Inventors:	Gilmour, Marvin
Application No.:	PCT/US01/47836 US 10/433,738
Attorney Docket No.:	NRNZ-1009

Title:	Compositions and methods for the rescue of white matter
Inventors:	Guan, Gunn, Bennet, Egan
Application No.:	PCT/US01/47749 US 60/254,349 US 60/287,668 US 10/013,812
Attorney Docket No.:	NRNZ-1010

Title:	Regulation of weight
Inventors:	Alexi
Application or Patent No.:	US 60/278,562 PCT/US02/07686 EP 02726620.4 US Patent No: 6,682,753
Attorney Docket No.:	NRNZ-1017

Title:	Neuronal Rescue Agent
Inventors:	Gluckman, Williams, Wu, Hughes, Lai
Application No.:	PCT/NZ98/00139
Attorney Docket No.:	NRNZ-1004WO

Title:	Neuronal Rescue Agent
Inventors:	Gluckman, Williams, Wu, Hughes, Lai
Patent No.:	AU 738,192
Attorney Docket No.:	NRNZ-1004AU

Title:	Regulation of tyrosine hydroxylase
Inventors:	Gluckman, Guan, Alexi
Application No. or Patent No.:	PCT/NZ99/00085 AU 751,217 CN 99807332.6 EP 99928258.5 JP 554388/2000 NZ 330,684 US Pat. No: 6,617,311 US Application No: 10/606,574
Attorney Docket No.:	NRNZ-1005

Title:	Neuroprotection
Inventors:	Scheepens, Williams, Gluckman, Clark
Application No. or Patent No.:	PCT/NZ99/00147 AU 757,907 CN 99810613.5 EP 99 946 457.1 BR 1991/13457-8 JP 568459/2000 NZ 510,253 US 09/786,982
Attorney Docket No.:	NRNZ-1006



Title:	GPE analogs and peptidomimetics
Inventors:	Abood, Brimble
Application No.:	PCT/US02/16361
Attorney Docket No.:	NRNZ-1018WO

Title:	GPE analogs and peptidomimetics
Inventors:	Abood, Brimble
Application No.:	JP 2002-592330
Attorney Docket No.:	NRNZ-1018JP0

Title:	GPE analogs and peptidomimetics
Inventors:	Abood, Brimble
Application No.:	EP 02731918.5
Attorney Docket No.:	NRNZ-1018EP0

Title:	GPE analogs and peptidomimetics
Inventors:	Abood, Brimble
Application No.:	US 10/155,864
Attorney Docket No.:	NRNZ-1018US1

Title:	Neuroprotection and /or neurorestoration via the neural activin type IIB receptor
Inventors:	Hughes, Fernandez, Raniga
Application No.:	PCT/US02/20111 US 60/300,514 US 10/177,735
Attorney Docket No.:	NRNZ-1019

Title:	Neuronal Restoration Agents
Inventors:	Wu, Williams
Application No.:	US 60/371,861
Attorney Docket No.:	NRNZ-1021

Title:	Compositions and methods for the treatment of brain damage
Inventors:	Sieg, Hughes
Application No.:	US 60/314,952 PCT/US02/26782
Attorney Docket No.:	NRNZ-1023

Title:	Neural Regeneration peptides and Methods for their Use in Treatment of Brain damage
Inventors:	Sieg, Hughes
Application No.:	US 10/225,838
Attorney Docket No.:	NRNZ-1023US1

Title:	Neural Regeneration Peptides and Methods for their Use in Treatment of Brain damage
Inventors:	Sieg, Gorba
Application No.:	US 60/516,018
Attorney Docket No.:	NRNZ-1023US3

Title:	Neural Regeneration peptides and Methods for their Use in Treatment of Brain damage
Inventors:	Sieg, Gorba
Application No.:	US 60/585,041
Attorney Docket No.:	NRNZ-1023US4

Title:	Treatment on demyelinating diseases
Inventors:	Krissansen, Kanwar
Application No.:	NZ 507,478 PCT/US01/32187 EP01981601.6
Attorney Docket No.:	NRNZ-1033

Title:	Treatment on demyelinating diseases
Inventors:	Krissansen, Kanwar
Application No.:	NZ 507,478 PCT/US01/32198 US 10/398,876
Attorney Docket No.:	NRNZ-1034

Title:	Cyclo(prolyl-glycine) and methods of use to treat neural disorders
Inventors:	Guan, Gluckman, Thomas, Sieg
Application No.:	NZ 515,371 NZ 515,432 NZ 515,551 PCT/US2002/036235
Attorney Docket No.:	NRNZ-1036

Title:	Compositions and methods for immunomodulation
Inventors:	Gluckman
Application No.:	PCT/US03/09714 US 60/370,788
Attorney Docket No.:	NRNZ-1038

Title:	Treatment of diabetes
Inventors:	Vickers
Application No.:	US 60/527,024
Attorney Docket No.:	NRNZ-1043

Title:	Compositions and Methods For the Treatment of Degenerative Diseases And Conditions of The Body
Inventors:	Gluckman, Egan
Application No.:	US 60/397,827 US 60/489,167
Attorney Docket No.:	NRNZ-1044

Title:	Use of Gly-Pro-Glu to Treat Spinal Cord and Peripheral Nerve Damage
Inventors:	Gluckman, Williams, Clarke, Sirimanne
Application No.	US 60/538,577
Attorney Docket No.	NRNZ-1046

Title:	Cyclic Proline-Containing Peptide Mimetics
Inventors:	Harris, Brimble
Application No.:	US 60/456,136 US 60/505,119 PCT/US04/008108
Attorney Docket No.:	NRNZ-1048

Title:	NEUROPROTECTIVE BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE
Inventors:	Brimble, Guan, Sieg
Application No.:	PCT/US04/28308
Attorney Docket No.:	NRNZ-1050

Title:	Neuroprotective Effects of Gly-Pro-Glu Following Intravenous Infusion
Inventors:	Guan, Thomas, Batchelor, Breier, Gluckman
Application No.:	US 60/553,688
Attorney Docket No.:	NRNZ-1052US2

Title:	Pharmacokinetics of GPE and methods of its administration
Inventors:	Batchelor, Thomas, Breier, Gluckman
Application No.:	US 60/515,397
Attorney Docket No.:	NRNZ-1052US1

Title:	Anti-GPE antibodies, their uses and analytical methods for GPE
Inventors:	Thomas, Breier, Batchelor
Application No.:	PCT/US02/08195
Attorney Docket No.:	NRNZ-1016WO0

Title:	Anti-GPE antibodies, their uses and analytical methods for GPE
Inventors:	Thomas, Breier, Batchelor
Application No.:	EP 02753654.9
Attorney Docket No.:	NRNZ-1016EP0

Title:	Anti-GPE antibodies, their uses and analytical methods for GPE
Inventors:	Thomas, Breier, Batchelor
Application No.:	US 10/100,515
Attorney Docket No.:	NRNZ-1016US1

Title:	GPE and GPE analogues /peptidomimetics and caffeineol improve sensory-motor function recovery after stroke in rats
Inventors:	Grotta, Gluckman
Application No.:	US 60/557,940
Attorney Docket No.:	NRNZ-1053US0

Title:	GPE and G2MePE in combination with caffeinol improve sensory motor function recovery after stroke
Inventors:	Grotta, Gluckman
Application No.:	US 60/572,627
Attorney Docket No.:	NRNZ-1053US1

WHEREAS, PATENT PROPERTY shall include each and all of the following:

- (a) each of the foregoing patents and patent applications therefore and all documents from which any of the above patents and patent applications claim priority and the inventions disclosed therein, and all embodiments of such inventions heretofore assigned to ASSIGNOR [all collectively hereinafter termed "Inventions"];
- (b) all rights to apply in any and all countries of the world for patents, certificates of invention or other governmental grants on said Inventions, including the right to apply for patents pursuant to the International Convention for the Protection of Industrial Property or pursuant to any other convention, treaty, agreement or understanding;
- (c) any and all applications filed and any and all patents, certificates of invention or other governmental grants granted on said inventions in each and every country, including each and every application filed and each and every patent granted on any application which is a division, substitution, or continuation of any of said applications;
- (d) each and every reissue or extension of any of said patents;
- (e) each and every patent claim resulting from a reexamination certificate for any and all of said patents, and
- (f) the right to sue for and all claims for damages, profits or other recovery resulting from infringement, including past infringement, of any of the foregoing.

WHEREAS Neuren Pharmaceuticals Ltd. (hereinafter termed "Assignee"), a New Zealand company having a place of business at Level 3, 2-6 Park Avenue, Grafton, Auckland, Country of New Zealand, is to acquire from ASSIGNOR the entire rights, title and interest in and to said Patent Property.

NOW THEREFORE, for good and valuable consideration acknowledged by said ASSIGNOR to have been received in full from said ASSIGNEE:

1. ASSIGNOR hereby sells, assigns, transfers and otherwise conveys to ASSIGNEE, and ASSIGNEE's successors, legal representatives and assigns, the entire right, title, and interest in and to the PATENT PROPERTY.
2. ASSIGNOR further agrees to execute and cause to be executed such additional instruments as may be necessary or desirable to confirm the transfer of rights as herein contemplated, to record the transfer of rights in the United States and throughout the world, and to permit ASSIGNEE, and ASSIGNEE's successors, legal representatives and assigns to enforce the PATENT PROPERTY.

IN WITNESS WHEREOF, ASSIGNOR has caused this instrument to be executed by its duly authorized officer and employee on ASSIGNMENT day 1<sup>st</sup> day of January, 2004 in the County of New Zealand

This ASSIGNMENT may be executed in counterparts. If this ASSIGNMENT is executed in counterparts, all counterparts together shall be considered to be a single instrument.

**Mayflower Ltd.**

By [Signature] (Sgt. [Name])

Name Act's Detective

The Director

Signature: \_\_\_\_\_

By: \_\_\_\_\_  
(Signature)

NAME: Mr. J. G. Smith

Total: Director

Signature: \_\_\_\_\_

**WITNESSES:**

SECRET

NAME: WILLIAM C.

Signature Date: \_\_\_\_\_

By: \_\_\_\_\_  
(Signature)

NAME: \_\_\_\_\_

Signature Line: \_\_\_\_\_

IN WITNESS WHEREOF, ASSIGNOR has caused this instrument to be executed by its duly authorized corporate officer and delivered to ASSIGNEE this 1<sup>st</sup> day of January, 2004 in the Country of New Zealand.

This ASSIGNMENT may be executed in counterparts. If this ASSIGNMENT is executed in counterparts, all counterparts together shall be considered to be a single instrument.

Neuron2 Ltd.

By: \_\_\_\_\_  
(Signature)

Name: Robin Congreve

Title: Director

Signature Date: \_\_\_\_\_

By:   
(Signature)

Name: Jim McLay

Title: Director

Signature Date: 15/10/04

Witnesses:

By: \_\_\_\_\_  
(Signature)

Name: \_\_\_\_\_

Signature Date: \_\_\_\_\_

By:   
(Signature)

Name: SANDY SCHADE

Signature Date: 15/10/04

\*\*\*\*\*